European Journal of Cancer
Volume 39, Issue 13 , Pages 1957-1966 , September 2003

Differential relationship between changes in tumour size and microcirculatory functions induced by therapy with an antivascular drug and with cytotoxic drugs: implications for the evaluation of therapeutic efficacy of AC7700 (AVE8062)

  • K. Hori

      Affiliations

    • Department of Vascular Biology, Division of Cancer Control, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aoba-ku, Sendai 980-8575, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81-22-717-8532; fax: +81-22-717-8533
    • ,
  • S. Saito

      Affiliations

    • Department of Vascular Biology, Division of Cancer Control, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aoba-ku, Sendai 980-8575, Japan
    • ,
  • Y. Sato

      Affiliations

    • Department of Vascular Biology, Division of Cancer Control, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aoba-ku, Sendai 980-8575, Japan
    • ,
  • H. Akita

      Affiliations

    • Second Department of Oral Anatomy, Graduate School of Dentistry, Tohoku University, 4-1 Seiryomachi, Aoba-ku, Sendai 980-8575, Japan
    • ,
  • T. Kawaguchi

      Affiliations

    • Second Department of Pathology, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan
    • ,
  • K. Sugiyama

      Affiliations

    • Division of Internal Medicine, Sendai Shakaihoken Hospital, 3-16 Tsutsumimachi, Aoba-ku, Sendai 981-8501, Japan
    • ,
  • H. Sato

      Affiliations

    • Division of Internal Medicine, Katta Hospital, 2-1 Ohtemachi, Shiroishi 989-0276, Japan

Received 6 November 2002 ,Revised 17 February 2003 ,Accepted 6 May 2003.

References 

  1. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia. 1989;45:209–211
  2. Nihei Y, Suzuki M, Okano A, et al.  Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn. J. Cancer Res. 1999;90:1387–1395
  3. Hori K, Saito S, Nihei Y, Suzuki M, Sato Y. Antitumor effects due to irreversible stoppage of tumor tissue blood flow (evaluation of a novel combretastatin A-4 derivative, AC7700). Jpn. J. Cancer Res. 1999;90:1026–1038
  4. Nihei Y, Suga Y, Morinaga Y, et al.  A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors. Jpn. J. Cancer Res. 1999;90:1016–1025
  5. Hori K, Saito S, Sato Y, Kubota K. Stoppage of blood flow in 3-methylcholanthrene-induced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect. Med. Sci. Monit. 2001;7:26–33
  6. Hori K, Saito S, Kubota K. A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br. J. Cancer. 2002;86:1604–1614
  7. Ohno T, Kawano K, Sasaki A, et al.  Antitumor and antivascular effects of AC-7700, a combretastatin A-4 derivative, against rat liver cancer. Int. J. Clin. Oncol. 2002;7:171–176
  8. Hori K, Suzuki M, Tanda S, Saito S. In vivo analysis of tumor vascularization in the rat. Jpn. J. Cancer Res. 1990;81:279–288
  9. Shimosato Y, Watanabe K. Enzymorphological observation on irradiated tumor, with a particular reference to acid hydrolase activity. I. Light microscopic study. Gann. 1967;58:541–550
  10. Hori K, Zhang Q-H, Li H-C, Saito S. Variation of growth rate of a rat tumour during a light-dark cycle (correlation with circadian fluctuations in tumour blood flow). Br. J. Cancer. 1995;71:1163–1168
  11. Ohsumi K, Nakagawa R, Fukuda Y, et al.  Novel combretastatin analogues effective against murine solid tumors (design and structure-activity relationships). J. Med. Chem. 1998;41:3022–3032
  12. Hatanaka T, Fujita K, Ohsumi K, et al.  Novel B-ring modified combretastatin analogues (syntheses and antineoplastic activity). Bioorg. Med. Chem. Lett. 1998;8:3371–3374
  13. Hori K, Suzuki M, Tanda S, Saito S, Shinozaki M, Zhang Q-H. Fluctuations in tumor blood flow under normotension and the effect of angiotensin II-induced hypertension. Jpn. J. Cancer Res. 1991;82:1309–1316
  14. Gullino PM, Grantham FH. Studies on the exchange of fluids between host and tumor. I. A method for growing ‘tissue-isolated’ tumors in laboratory animals. J. Natl. Cancer Inst. 1961;27:679–693
  15. Peterson H-I. Tumor blood flow compared with normal tissue blood flow. In:  Peterson H-I editors. Tumor Blood Circulation: Angiogenesis, Vascular Morphology and Blood Flow of Experimental and Human Tumors. Florida, CRC Press: Boca Raton; 1979;p. 103–114
  16. Hori K, Suzuki M, Tanda S, Saito S. Characterization of heterogeneous distribution of tumor blood flow in the rat. Jpn. J. Cancer Res. 1991;82:109–117
  17. Aukland K, Bower BF, Berliner RW. Measurement of local blood flow with hydrogen gas. Circ. Res. 1964;14:164–187
  18. Hori K, Suzuki M, Tanda S, Saito S, Shinozaki M, Zhang Q-H. Circadian variation of tumor blood flow in rat subcutaneous tumors and its alteration by angiotensin II-induced hypertension. Cancer Res. 1992;52:912–916
  19. Paskins-Hurlburt AJ, Hollenberg NK, Abrams HL. Tumor perfusion in relation to the rapid growth phase and necrosis (studies on the Walker carcinoma in the rat testicle). Microvasc. Res. 1982;24:15–24
  20. Yamaura H, Sato H. Quantitative studies on the developing vascular system of rat hepatoma. J. Natl. Cancer Inst. 1974;53:1229–1240
  21. Hori K, Suzuki M, Abe I, Saito S, Sato H. Increased tumor tissue pressure in association with the growth of rat tumors. Jpn. J. Cancer Res. 1986;77:65–73
  22. Wiig H, Tveit E, Hultborn R, Reed RK, Weiss L. Interstitial fluid pressure in DMBA-induced rat mammary tumors. Scand. J. Clin. Lab. Invest. 1982;42:159–164
  23. Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 1987;6:559–593
  24. Hori K, Zhang Q-H, Li H-C, Saito S, Sato Y. Timing of cancer chemotherapy based on circadian variations in tumor tissue blood flow. Int. J. Cancer. 1996;65:360–364
  25. Rubin P, Casarett G. Microcirculation of tumors. II. The supervascularized state of irradiated regressing tumors. Clin. Radiol. 1966;17:346–355
  26. Sato K. Histological analysis of chemotherapeutic effects in cancer patients treated with angiotensin-induced hypertension chemotherapy. Kosankinbyo Kenkyusho Zasshi. 1983;35:145–155 (in Japanese)
  27. Sato H, Sugiyama K, Hoshi M, Urushiyama M, Ishizuka K. Angiotensin II (AII) induced hypertension chemotherapy (IHC) for unresectable gastric cancer (with reference to resection after down staging). World J. Surg. 1995;19:836–842
  28. Gee MS, Saunders HM, Lee JC, et al.  Doppler ultrasound imaging detects changes in tumor perfusion during antivascular therapy associated with vascular anatomic alterations. Cancer Res. 2001;61:2974–2982
  29. Pahernik S, Griebel J, Botzlar A, et al.  Quantitative imaging of tumour blood flow by contrast-enhanced magnetic resonance imaging. Br. J. Cancer. 2001;85:1655–1663
  30. Pahernik S, Harris AG, Schmitt-Sody M, et al.  Orthogonal polarization spectral imaging as a new tool for the assessment of antivascular tumour treatment in vivo (a validation study). Br. J. Cancer. 2002;86:1622–1627

PII: S0959-8049(03)00429-5

doi: 10.1016/S0959-8049(03)00429-5

European Journal of Cancer
Volume 39, Issue 13 , Pages 1957-1966 , September 2003

Article Tools

* Image Usage & Resolution